Imaging prostate cancer using a novel PET agent
A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
NA · Peking University First Hospital · NCT05940259
This study is testing a new imaging agent to see if it can help doctors better diagnose prostate cancer and other related cancers in patients who have or might have the disease.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | Male |
| Sponsor | Peking University First Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05940259 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of a new PET imaging agent, [68Ga]P3, which targets prostate-specific membrane antigen (PSMA) to enhance the diagnosis of prostate cancer and other malignancies with high PSMA expression. The approach leverages the specificity of PSMA, which is prevalent in prostate cancer cells and tumor blood vessels, to improve imaging accuracy. Patients with confirmed or suspected cancer will be enrolled to assess the effectiveness of this imaging technique in clinical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with confirmed or suspected cancer who can provide informed consent.
Not a fit: Patients without cancer or those who do not express PSMA may not benefit from this imaging approach.
Why it matters
Potential benefit: If successful, this imaging technique could lead to more accurate diagnoses and better treatment planning for patients with prostate cancer and other PSMA-expressing tumors.
How similar studies have performed: Other studies have shown promising results with similar PSMA-targeted imaging approaches, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria:
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Xing Yang, Dr.
- Email: yangxing2017@bjmu.edu.cn
- Phone: +861083572928
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neoplasms, [68Ga]P3, PSMA, PET/CT